FDA
-
-
-
-
-
-
-
Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board
-
-
-
-
-
-
-
Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress
-
-
-
-
-
-
-
Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care
-
-
-
-
-
-
-
Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones
-
-
-
-
-
-
-
Psyence Biomed Announces Registration Statement on Form F-1 for Up to $25 Million Equity Line of Credit with White Lion Capital, LLC, Declared Effective by SEC
-
-
-
-
-
-
-
Psyence Group's NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study
-
-
-
-
-
-
-
Psyence Group Announces Cantheon Capital Private Placement
-
327,066 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

